349 1.36 1.07 1.24 0.97 1.05 1.26 0.90 0.99, 1.88 0.77, 1.50 0.89, 1.74 0.70, 1.33 0.75, 1.46 0.90, 1.77 0.64, 1.25 88 98 104 88 99 102 103 349 350 350 349 349 350 349 1.06 0.75, 1.48 1.18 0.84, 1.64 1.28 0.92, 1.79 0.88 0.63, 1.22 1.13 0.81, 1.58 1.31 0.93, 1.83 1.09 0.79, 1.51 82 96 90 89 88 90 88 350 349 349 350 350 349 350 0.99 1.15 1.07 0.89 1.00 1.14 0.92 0.70, 1.41 0.83, 1.61 0.75, 1.52 0.64, 1.24 0.70, 1.41 0.80, 1.63 0.66, 1.30 0.59 0.34 0.70 0.41 0.90 0.45 0.Serum Phospholipid Fatty Acids and Prostate CancerAbbreviations: CARET, Carotene and Retinol Efficacy Trial; CI, self-confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; OR, odds ratio; PUFA, polyunsaturated fatty acid. a Multivariate adjustment for age at enrollment (continuous), race (white, black, other folks), CARET randomization assignment (retinol plus -carotene, placebo), household history of prostate cancer in first-degree relatives (yes, no), alcohol consumption (nondrinker, beneath median, at or above median, unknown), smoking status (existing, former/never), smoking pack-years (40, 40, 60, 60), and physique mass index (continuous). b Defined as stage 0 I tumors and Gleason score 7.1112 Cheng et al.Table four. Multivariable-adjusteda Association of Serum n-3 and n-6 Polyunsaturated Fatty Acids With Aggressive Prostate Cancerb Risk within the Carotene and Retinol Efficacy Trial, 1985Quartile 1 Fatty Acids No. of Circumstances No. of Controls OR 95 CI No. of Instances Quartile 2 No. of Controls OR 95 CI No. of Cases Quartile 3 No. of Controls OR 95 CI No. of Instances Quartile four No. of Controls OR 95 CI Ptrendn-3 PUFAs -Linolenic acid Eicosatrienoic acid Eicosapentaenoic acid Docosapentaenoic acid Docosahexaenoic acid EPA + DHA Total n-3 n-6 PUFAs Linoleic acid -Linolenic acid Eicosadienoic acid Dihomo–linolenic acid Arachidonic acid Docosadienoic acid Docosatetraenoic acid Total n-6 65 75 69 70 73 54 76 77 349 350 350 349 350 350 350 350 1.(-)-Epicatechin Endogenous Metabolite 00 1.Pertussis Toxin Description 00 1.00 1.00 1.00 1.00 1.00 1.00 Referent Referent Referent Referent Referent Referent Referent Referent 64 58 56 65 72 72 91 52 350 349 349 350 349 349 349 349 0.96 0.73 0.80 0.92 1.02 1.38 1.22 0.69 0.65, 1.40 0.50, 1.07 0.54, 1.18 0.63, 1.34 0.71, 1.46 0.94, two.03 0.86, 1.72 0.47, 1.02 71 71 81 65 71 73 55 77 350 349 350 349 349 349 349 349 1.07 0.73, 1.55 0.85 0.59, 1.23 1.19 0.83, 1.70 0.95 0.65, 1.38 1.02 0.71, 1.46 1.39 0.94, two.04 0.75 0.51, 1.10 1.07 0.75, 1.53 73 69 67 73 57 74 51 67 349 349 349 350 350 350 350 350 1.15 0.83 0.96 1.03 0.83 1.46 0.PMID:24179643 69 0.95 0.79, 1.70 0.57, 1.20 0.66, 1.40 0.71, 1.51 0.56, 1.23 0.99, 2.14 0.46, 1.02 0.66, 1.38 0.38 0.48 0.63 0.84 0.42 0.08 0.011 0.70 65 62 54 71 63 65 66 350 350 350 349 349 350 350 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Referent Referent Referent Referent Referent Referent 87 72 69 69 81 62 69 349 349 349 350 350 349 349 1.33 1.20 1.25 0.94 1.30 0.97 1.07 0.93, 1.90 0.82, 1.74 0.85, 1.85 0.65, 1.36 0.90, 1.87 0.66, 1.42 0.74, 1.55 62 65 77 67 62 79 68 349 350 350 349 349 350 349 0.99 0.67, 1.45 1.07 0.73, 1.57 1.32 0.90, 1.94 0.93 0.64, 1.35 1.05 0.71, 1.56 1.23 0.85, 1.78 1.06 0.73, 1.55 59 74 73 66 67 67 70 350 349 349 350 350 349 350 0.93 1.27 1.20 0.91 1.10 1.05 1.07 0.62, 1.37 0.88, 1.85 0.81, 1.79 0.63, 1.32 0.74, 1.63 0.71, 1.55 0.73, 1.57 0.39 0.31 0.38 0.63 0.92 0.53 0.Am J Epidemiol. 2013;177(10):1106Abbreviations: CARET, Carotene and Retinol Efficacy Trial; CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; OR, odds ratio; PUFA, polyunsaturated fa.
